



Request for Prior Authorization
THROMBOPOIETIN RECEPTOR AGONISTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Form with fields for IA Medicaid Member ID #, Patient name, DOB, Patient address, Provider NPI, Prescriber name, Phone, Prescriber address, Fax, Pharmacy name, Address, Phone, Pharmacy NPI, Pharmacy fax, NDC.

Payment for a non-preferred thrombopoietin receptor agonist will be considered following documentation of a recent trial and therapy failure with a preferred thrombopoietin receptor agonist unless such a trial would be medically contraindicated.

Preferred Non-Preferred Strength Dosage Instructions Quantity Days Supply
Promacta Nplate

Diagnosis:

Chronic Immune Thrombocytopenic Purpura (ITP) (Promacta and Nplate)

Treatment failure with a preferred corticosteroid or immunoglobulin product:

Documentation of an insufficient response to a corticosteroid, an immunoglobulin, or the patient has undergone splenectomy is required prior to consideration of a thrombopoietin receptor agonist.

Trial Drug Name:

Trial start date: Trial end date:

Failure reason:

Has the patient undergone splenectomy? No Yes

Chronic Hepatitis C Associated Thrombocytopenia (Promacta)

Payment will be considered to allow for initiation and/or maintenance of interferon-based therapy with ribavirin when the patient has a baseline platelet count less than 75 x 10^9/L. Requests will not be considered under the following conditions: 1. Patients taking direct acting antiviral agents for the treatment of chronic hepatitis C infection in addition to interferon based therapy with ribavirin. 2. Patients taking direct acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. 3. Patients with decompensated liver disease with a Child-Pugh score > 6 (Class B & C). 4. Patients with a history of ascites. 5. Patients with hepatic encephalopathy.

- Baseline platelet count: Lab Date:
Patient using direct acting antiviral agents without interferon: Yes No
Patient has decompensated liver disease with a Child-Pugh score > 6 (Class B & C): Yes No
Patient has a history of ascites: Yes No
Patient has hepatic encephalopathy: Yes No



Request for Prior Authorization
THROMBOPOIETIN RECEPTOR AGONISTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

[ ] Severe Aplastic Anemia (Promacta)

Payment will be considered under the following conditions: 1. Patient has documentation of an insufficient response or intolerance to at least one prior immunosuppressive therapy; and 2. Patient has a platelet count <= 30 x 10^9/L. 3. If criteria for coverage are met, initial authorization will be given for 16 weeks. Documentation of hematologic response after 16 weeks of therapy will be required for further consideration.

Trial Drug Name: \_\_\_\_\_

Trial start date: \_\_\_\_\_ Trial end date: \_\_\_\_\_

Failure reason: \_\_\_\_\_

• Platelet count: \_\_\_\_\_ Lab Date: \_\_\_\_\_

Renewal Requests:

• Has patient had a hematologic response after 16 weeks of Promacta therapy? [ ] Yes (attach labs) [ ] No

Reason for use of Non-Preferred drug requiring prior approval: \_\_\_\_\_

Other medical conditions to consider: \_\_\_\_\_

Attach lab results and other documentation as necessary.

Table with 2 columns: Prescriber signature (Must match prescriber listed above.) and Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.